BACKGROUND: The genetic basis of susceptibility to prostate cancer (PRCA) remains elusive. Mutations in BRCA2 have been associated with increased prostate cancer risk and account for around 2% of young onset (<56 years) prostate cancer cases. PALB2 is a recently identified breast cancer susceptibility gene whose protein is closely associated with BRCA2 and is essential for BRCA2 anchorage to nuclear structures. This functional relationship made PALB2 a candidate PRCA susceptibility gene. METHODS: We sequenced PALB2 in probands from 95 PRCA families, 77 of which had two or more cases of early onset PRCA (age at diagnosis <55 years), and the remaining 18 had one case of early onset PRCA and five or more total cases of PRCA. RESULTS: Two previously unreported variants, K18R and V925L were identified, neither of which is in a known PALB2 functional domain and both of which are unlikely to be pathogenic. No truncating mutations were identified. CONCLUSIONS: These results indicate that deleterious PALB2 mutations are unlikely to play a significant role in hereditary prostate cancer.
BACKGROUND: The genetic basis of susceptibility to prostate cancer (PRCA) remains elusive. Mutations in BRCA2 have been associated with increased prostate cancer risk and account for around 2% of young onset (<56 years) prostate cancer cases. PALB2 is a recently identified breast cancer susceptibility gene whose protein is closely associated with BRCA2 and is essential for BRCA2 anchorage to nuclear structures. This functional relationship made PALB2 a candidate PRCA susceptibility gene. METHODS: We sequenced PALB2 in probands from 95 PRCA families, 77 of which had two or more cases of early onset PRCA (age at diagnosis <55 years), and the remaining 18 had one case of early onset PRCA and five or more total cases of PRCA. RESULTS: Two previously unreported variants, K18R and V925L were identified, neither of which is in a known PALB2 functional domain and both of which are unlikely to be pathogenic. No truncating mutations were identified. CONCLUSIONS: These results indicate that deleterious PALB2 mutations are unlikely to play a significant role in hereditary prostate cancer.
Authors: Stephen M Edwards; Zsofia Kote-Jarai; Julia Meitz; Rifat Hamoudi; Questa Hope; Peter Osin; Rachel Jackson; Christine Southgate; Rashmi Singh; Alison Falconer; David P Dearnaley; Audrey Ardern-Jones; Annette Murkin; Anna Dowe; Jo Kelly; Sue Williams; Richard Oram; Margaret Stevens; Dawn M Teare; Bruce A J Ponder; Simon A Gayther; Doug F Easton; Rosalind A Eeles Journal: Am J Hum Genet Date: 2002-12-09 Impact factor: 11.025
Authors: M P Matikaine; E Pukkala; J Schleutker; T L Tammela; P Koivisto; R Sankila; O P Kallioniemi Journal: Cancer Causes Control Date: 2001-04 Impact factor: 2.506
Authors: Cezary Cybulski; Tomasz Huzarski; Bohdan Górski; Bartłomiej Masojć; Marek Mierzejewski; Tadeusz Debniak; Bartłomiej Gliniewicz; Joanna Matyjasik; Elzbieta Złowocka; Grzegorz Kurzawski; Andrzej Sikorski; Michał Posmyk; Marek Szwiec; Ryszard Czajka; Steven A Narod; Jan Lubiński Journal: Cancer Res Date: 2004-04-15 Impact factor: 12.701
Authors: J Simard; M Dumont; D Labuda; D Sinnett; C Meloche; M El-Alfy; L Berger; E Lees; F Labrie; S V Tavtigian Journal: Endocr Relat Cancer Date: 2003-06 Impact factor: 5.678
Authors: E H Seppälä; T Ikonen; N Mononen; V Autio; A Rökman; M P Matikainen; T L J Tammela; J Schleutker Journal: Br J Cancer Date: 2003-11-17 Impact factor: 7.640
Authors: Sanna Pakkanen; Tiina Wahlfors; Sanna Siltanen; Mimmi Patrikainen; Mika P Matikainen; Teuvo L J Tammela; Johanna Schleutker Journal: J Negat Results Biomed Date: 2009-12-15
Authors: Xin Yang; Goska Leslie; Alicja Doroszuk; Sandra Schneider; Jamie Allen; Brennan Decker; Alison M Dunning; James Redman; James Scarth; Inga Plaskocinska; Craig Luccarini; Mitul Shah; Karen Pooley; Leila Dorling; Andrew Lee; Muriel A Adank; Julian Adlard; Kristiina Aittomäki; Irene L Andrulis; Peter Ang; Julian Barwell; Jonine L Bernstein; Kristie Bobolis; Åke Borg; Carl Blomqvist; Kathleen B M Claes; Patrick Concannon; Adeline Cuggia; Julie O Culver; Francesca Damiola; Antoine de Pauw; Orland Diez; Jill S Dolinsky; Susan M Domchek; Christoph Engel; D Gareth Evans; Florentia Fostira; Judy Garber; Lisa Golmard; Ellen L Goode; Stephen B Gruber; Eric Hahnen; Christopher Hake; Tuomas Heikkinen; Judith E Hurley; Ramunas Janavicius; Zdenek Kleibl; Petra Kleiblova; Irene Konstantopoulou; Anders Kvist; Holly Laduca; Ann S G Lee; Fabienne Lesueur; Eamonn R Maher; Arto Mannermaa; Siranoush Manoukian; Rachel McFarland; Wendy McKinnon; Alfons Meindl; Kelly Metcalfe; Nur Aishah Mohd Taib; Jukka Moilanen; Katherine L Nathanson; Susan Neuhausen; Pei Sze Ng; Tu Nguyen-Dumont; Sarah M Nielsen; Florian Obermair; Kenneth Offit; Olufunmilayo I Olopade; Laura Ottini; Judith Penkert; Katri Pylkäs; Paolo Radice; Susan J Ramus; Vilius Rudaitis; Lucy Side; Rachel Silva-Smith; Valentina Silvestri; Anne-Bine Skytte; Thomas Slavin; Jana Soukupova; Carlo Tondini; Alison H Trainer; Gary Unzeitig; Lydia Usha; Thomas van Overeem Hansen; James Whitworth; Marie Wood; Cheng Har Yip; Sook-Yee Yoon; Amal Yussuf; George Zogopoulos; David Goldgar; John L Hopper; Georgia Chenevix-Trench; Paul Pharoah; Sophia H L George; Judith Balmaña; Claude Houdayer; Paul James; Zaki El-Haffaf; Hans Ehrencrona; Marketa Janatova; Paolo Peterlongo; Heli Nevanlinna; Rita Schmutzler; Soo-Hwang Teo; Mark Robson; Tuya Pal; Fergus Couch; Jeffrey N Weitzel; Aaron Elliott; Melissa Southey; Robert Winqvist; Douglas F Easton; William D Foulkes; Antonis C Antoniou; Marc Tischkowitz Journal: J Clin Oncol Date: 2019-12-16 Impact factor: 44.544
Authors: Timothy R Rebbeck; Nandita Mitra; Susan M Domchek; Fei Wan; Tara M Friebel; Teo V Tran; Christian F Singer; Muy-Kheng Maria Tea; Joanne L Blum; Nadine Tung; Olufunmilayo I Olopade; Jeffrey N Weitzel; Henry T Lynch; Carrie L Snyder; Judy E Garber; Antonis C Antoniou; Susan Peock; D Gareth Evans; Joan Paterson; M John Kennedy; Alan Donaldson; Huw Dorkins; Douglas F Easton; Wendy S Rubinstein; Mary B Daly; Claudine Isaacs; Heli Nevanlinna; Fergus J Couch; Irene L Andrulis; Eitan Freidman; Yael Laitman; Patricia A Ganz; Gail E Tomlinson; Susan L Neuhausen; Steven A Narod; Catherine M Phelan; Roger Greenberg; Katherine L Nathanson Journal: Cancer Res Date: 2011-07-28 Impact factor: 12.701
Authors: Laurence H Pearl; Amanda C Schierz; Simon E Ward; Bissan Al-Lazikani; Frances M G Pearl Journal: Nat Rev Cancer Date: 2015-03 Impact factor: 60.716
Authors: Dominika Wokołorczyk; Wojciech Kluźniak; Klaudia Stempa; Bogna Rusak; Tomasz Huzarski; Jacek Gronwald; Katarzyna Gliniewicz; Aniruddh Kashyap; Sylwia Morawska; Tadeusz Dębniak; Anna Jakubowska; Marek Szwiec; Paweł Domagała; Jan Lubiński; Steven A Narod; Mohammad R Akbari; Cezary Cybulski Journal: Br J Cancer Date: 2021-05-18 Impact factor: 7.640
Authors: Liisa M Pelttari; Riikka Nurminen; Alexandra Gylfe; Lauri A Aaltonen; Johanna Schleutker; Heli Nevanlinna Journal: BMC Cancer Date: 2012-11-23 Impact factor: 4.430